Maxim Group set a $7.00 target price on Can Fite Biopharma (NYSEAMERICAN:CANF) in a research note released on Monday, December 18th. The firm currently has a buy rating on the biotechnology company’s stock.
Several other equities analysts also recently weighed in on CANF. HC Wainwright reaffirmed a buy rating on shares of Can Fite Biopharma in a report on Tuesday, October 31st. ValuEngine downgraded shares of Can Fite Biopharma from a sell rating to a strong sell rating in a report on Thursday, September 7th.
Shares of Can Fite Biopharma (CANF) traded down $0.11 during mid-day trading on Monday, hitting $1.82. 371,132 shares of the stock were exchanged, compared to its average volume of 269,816. Can Fite Biopharma has a 52-week low of $1.24 and a 52-week high of $2.67. The company has a market capitalization of $25.30, a price-to-earnings ratio of 6.24 and a beta of 1.37.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/11/can-fite-biopharma-canf-pt-set-at-7-00-by-maxim-group.html.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.